A 12-Week Randomized, Open-Label, Active Comparator Period Followed by a 12-Week Safety Extension Period to Evaluate the Safety and Efficacy of Fesoterodine in Subjects Aged 6 to 16 Years and > 25 KG with Symptoms of Detrusor Overactivity Associated with